Follow the AlzeCure Pharma AB share price and the full directors' dealings record of the company, a listed issuer based in Finland. Shares trade on FI FI, under the supervision of FIN-FSA. Operating in the Health Care sector, AlzeCure Pharma AB has logged 5 reports. Market capitalisation: €1bn. The latest transaction was filed on 1 July 2026 (Purchase). Among the most active insiders: Thomas Pollare. All data is free.
5
Insider Decl.
0
Thresholds
€212,096
5 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate AlzeCure Pharma AB Strong Buy (bullish), based on 1 analysts. Average price target: SEK 8.80.
26Σ signal
Buys €212,096· Sells
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
568,030 shares@ €0.19650.070% mcap100.0% of flowBTA (betald tecknad aktie)FI:A003R016-1
Ideal exit: 19 Apr 2026 (T+270)
5 of 5 declarations
About AlzeCure Pharma AB
AlzeCure Pharma AB is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease. It is listed on the XSTO market.